David Vega-Morales

Dr. David Vega-Morales

Insituto Mexicano del Seguro Social, Monterrey, Nuevo León, Mexico
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SBSytske Anne Bergstra
Sytske Anne Bergstra
Jaime BrancoJaime Branco
Jaime Branco
DVDavid Vega-Morales
David Vega-Morales
KSKaren Salomon-Escoto
Karen Salomon-Escoto
NGNimmisha Govind
Nimmisha Govind
RLRobert B M Landewé
Robert B M Landewé
Objective To establish in a global setting the relationships between countries’ socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes. To assess if prescription and reimbursement rules and generic access to medication relates to a countries’ bDMARD-usage. Methods Data on disease activity and drug use from countries that had contributed at least 100 patients were extracted from the METEOR database. Mean disease outcomes of all available patients at the final visit were calculated on a per-country basis. A questionnaire was sent to at least two rheumatologists per country inquiring about DMARD-prices, access to treatment and valid regulations for prescription and reimbursement. Results Data from 20 379 patients living in 12 different countries showed that countries’ SES was positively associated with measured disease activity (meanDAS28), but not always with physical functioning (HAQ-score). A lower country’s SES, stricter rules for prescription and reimbursement of bDMARDs as well as worse affordability of bDMARDs were associated with lower bDMARD-usage. bDMARD-usage was negatively associated with disease activity (although not with physical functioning), but the association was moderate at best. Conclusions Disease activity in patients with rheumatoid arthritis as well as bDMARD-usage varies across countries worldwide. The (negative) relationship between countries’ bDMARD-usage and level of disease activity is complex and under the influence of many factors, including—but not limited to—countries’ SES, affordability of bDMARDs and valid prescription and reimbursement rules for bDMARDs.

10 February 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LLLuis Iván Lozano-Plata
Luis Iván Lozano-Plata
DVDavid Vega-Morales
David Vega-Morales
JEJorge Antonio Esquivel-Valerio
Jorge Antonio Esquivel-Valerio
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
RRRaúl Díaz-Niño de Rivera
Raúl Díaz-Niño de Rivera

14 March 2015 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LPL. Pérez-Barbosa
L. Pérez-Barbosa
JEJ. A. Esquivel-Valerio
J. A. Esquivel-Valerio
AAA. C. Arana-Guajardo
A. C. Arana-Guajardo
DVDavid Vega-Morales
David Vega-Morales
JRJ. Riega-Torres
J. Riega-Torres
MGM. A. Garza-Elizondo
M. A. Garza-Elizondo

1 March 2015 in Reumatología Clínica
Verified
Journal Article
Closed access
MVMaría del Carmen Velarde-Ochoa
María del Carmen Velarde-Ochoa
JEJorge Antonio Esquivel-Valerio
Jorge Antonio Esquivel-Valerio
DVDavid Vega-Morales
David Vega-Morales
CSCassandra Michele Skinner-Taylor
Cassandra Michele Skinner-Taylor
DGDionicio Ángel Galarza-Delgado
Dionicio Ángel Galarza-Delgado
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo

25 May 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SBSytske Anne Bergstra
Sytske Anne Bergstra
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
ACArvind Chopra
Arvind Chopra
LWLai-Ling Winchow
Lai-Ling Winchow
DVDavid Vega-Morales
David Vega-Morales
RLRobert Bm Landewé
Robert Bm Landewé
Objective Age at rheumatoid arthritis (RA) onset varies by geographical latitude. We have investigated to what extent differences in patient-specific factors and country-level socioeconomic indicators explain this variability. Methods Patients with RA from the worldwide METEOR registry were included. Bayesian multilevel structural equation models were used to study the relationship between the absolute value of (hospital) geographical latitude and age at diagnosis (as a proxy for age at RA onset). We examined to what extent this effect is mediated by individual patient characteristics and by country-specific socioeconomic indicators and disentangled whether the observed effects occurred at the patient, hospital, or country levels. Results We included 37 981 patients from 93 hospitals in 17 geographically widespread countries. Mean age at diagnosis per country ranged from 39 (Iran) to 55 (Netherlands) years. Per degree increase in country latitude (between 9.9° and 55.8°), mean age at diagnosis increased by 0.23 years (95% credibility interval: 0.095 to 0.38) (reflecting >10 years difference in age at RA onset). For hospitals within a country, this latitude effect was negligible. Inclusion of patient-specific factors (eg, gender, anticitrullinated protein antibodies status) in the model augmented the main effect from 0.23 to 0.36 years. Inclusion of country-level socioeconomic indicators (eg, gross domestic product per capita) in the model almost effaced the main effect (from 0.23 to 0.051 (−0.37 to 0.38)). Conclusions Patients living closer to the equator get RA at a younger age. This latitude gradient was not explained by individual patient characteristics, but rather by countries’ socioeconomic status, providing a direct link between countries’ level of welfare and the clinical onset of RA.

1 March 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
DVDavid Vega-Morales
David Vega-Morales
MBMarta Barrón-Almazán
Marta Barrón-Almazán
AAAna Arana-Guajardo
Ana Arana-Guajardo